Kalydeco 150 MG tablet 56S
Ended Awarded Last action
- Contract number
- SPE2DR26FHKT1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,869
Award facts
- Contract value 100% obligated
- $18,869.22 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $18,869.22 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Kalydeco 150 mg tablets (56-count units). The award, issued on December 11, 2025, with an ultimate completion date of December 12, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion enterprise-wide acquisition strategy designed to support Department of Defense healthcare operations globally.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status and extensive product portfolio spanning branded and generic pharmaceuticals, biologics, vaccines, and specialty medical consumables. The PPV-G GEN V contract, awarded on November 13, 2025, with a ceiling value of $499,999,999 and completion date of December 31, 2036, comprises a 30-month base period with three 30-month option periods. Through this vehicle, the contractor supplies recurring pharmaceutical needs to military healthcare facilities worldwide, with the current delivery order for Kalydeco—a cystic fibrosis treatment—representing one of numerous orders issued to support the specialized pharmaceutical requirements of the Department of Defense medical system.
Quick answers
Who was awarded contract SPE2DR26FHKT1?
SPE2DR26FHKT1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 11, 2025.
How much is contract SPE2DR26FHKT1 worth?
The government has obligated $18,869 on SPE2DR26FHKT1.
Is contract SPE2DR26FHKT1 an order under another contract?
Yes. SPE2DR26FHKT1 is a delivery order under SPE2DR25D9222, an indefinite delivery contract.
Was contract SPE2DR26FHKT1 competed?
The extent of competition for SPE2DR26FHKT1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award